Is there a danger of getting Guillain-Barré Syndrome from the H1N1 flu vaccine?
Since Guillain-Barré Syndrome (GBS) is so rare, it is usually not seen as an adverse event following immunization in the clinical trial stage. In order to assess the potential risk, if any, of GBS following H1N1 flu vaccine, we need to observe a larger population. The risk of getting GBS after any flu vaccine is about one case for every million doses distributed. The benefit of the vaccine outweighs this theoretical risk.
